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ABSTRACT  
Epigenomic disruption has emerged as a common hallmak of human cancer. Single 
epigenetic markers, such as the use of the promoter hypermethylation-asssociated 
inactivation of the DNA repair enzyme MGMT to predict response to temozolomide in 
gliomas, are starting to be incorporated in the clinical setting, however, at the “omics” 
level there are not validated examples of its translational use. We have recently provided 
one example of how epigenomics can enter the clinical arena by demonstrating its value 
in the identification of the site of origin in the cancer of unknown primary (CUP). 
Identifying the origin of metastatic tumors remains a challenge in the diagnostic and 
clinical management of CUP. In spite of the great diagnostic advances made in the last 
decade, traditional diagnostic procedures can only identify the origin of about 30% of 
CUP cases. Thus, development of diagnostic strategies in the field of molecular biology 
has emerged as a way of complementing traditional procedures, and thereby improving 
CUP patient management. DNA methylation signatures are suitable for measurement in 
easily obtained samples, such as paraffin-embedded tissue or liquid biopsies, which is a 
competitive advantage when trying to implement a molecular diagnostic tool. The aim of 
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the review is to systematically organize the most recent data about epigenetics, CUPs 
and the role of other molecular markers, and to highlight areas for further research to 
engage the medical community in this exciting subject.  
Personalized oncology has been possible partly thanks to our improved understanding of 
cancer molecular biology and to the huge technical advances in methodology and 
analytical tools.  These advances have allowed us to identify molecular targets that cause 
diseases and understand how to counteract them.  Since the first human genome was 
determined in 1991, the amount of data generated using next-generation technologies 
has grown enormously.1  Due to the need to manage all this valuable information, several 
consortia have been created, such as the Cancer Genome Atlas (TCGA), whose aim is to 
elucidate the most frequent molecular alterations in different kinds of cancer.2,3  The 
central hallmarks of cancer cells were defined on the basis of the data generated,4 
providing a more comprehensive knowledge of cancer cell behavior and boosting the 
numbers of potential targets for therapy and of their associated biomarkers that may be of 
use in predicting treatment effectiveness. In the last decade, translational research in 
cancer has focused on finding molecular markers that may improve patient outcome and 
quality of life.  However, besides identifying prognostic factors to characterize those 
tumors that more likely to relapse, it is crucial to identify biomarkers that allow the tumors 
to be correctly classified and their diagnosis and outcome thereby to be optimized.  This 
will avoid the use of inefficient therapies and will reduce the health costs arising. These 
two aspects are of particular relevance to metastatic lesions of unknown origin, since 
these cannot be classified as a particular neoplasia and so have to be treated empirically, 
resulting in the notably poor survival rates in cancer of unknown primary (CUP).  
In the era of targeted therapy, it is essential to obtain an accurate histopathological and 
molecular classification of tumors in order to administer the best tailored therapeutic 
strategy.  Epigenetic alterations have served this purpose, since cancer cells are 
characterized by a massive overall loss of DNA methylation (20-60% decrease in global 
5-methylcytosine),5,6 and simultaneously by the acquisition of specific patterns of 
hypermethylation at CpG islands of certain promoters, which can reversibly or irreversibly 
alter gene function and contribute to cancer progression.7,8  Given the importance of 
epigenetics in neoplasia development, it is worth highlighting its attractiveness in 
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personalized oncology, as well as its already demonstrated usefulness in the diagnosis of 
cancers.  An association observed between epigenetic signatures and different tissues 
has enabled the discrimination among tumor types, not only according to their embryonic 
origin, but also on the basis of their tissue type.9  Recently, we have applied this 
approach to the generation of an epigenetic-based bioinformatic tool that allows the 
prediction of the primary tumor type from which a CUP metastatic lesion originates.10  An 
additional advantage of epigenetic translation to clinical practice comes from the nature of 
the material interrogated, DNA, a molecule that is stable over time, irrespective of the 
method of tissue fixation, and that it is not very reactive to change due to minimal external 
factors, unlike RNA expression levels.  Moreover, interesting progress is being made in 
the applying epigenetic tests in newer and less intrusive diagnostic materials, such as 
liquid biopsies.  
Taking into account the recent advances in the field of epigenomics, the purpose of this 
review is to put into context the state of our knowledge of CUP and the current diagnostic 
strategies, emphasizing the role of epigenetic signatures in clinical management, with the 
point of view focused on the present and the future.  It is also important to inspire the 
interest of the health community in epigenetics, highlighting the great benefits it might 
provide to clinics.  
Introduction to cancer of unknown primary  
The primary tissue of origin of 3-10% of all cancers diagnosed worldwide cannot be 
determined.11–13 This uncertainty has a direct impact on the outcome of patients.  Under 
such circumstances, in which the metastases are clinically manifested, but the primary 
tumor originating them is unknown, the physician diagnoses patients as having cancer of 
unknown primary (CUP). Clinically, CUP is defined as a histologically confirmed 
malignant tumor, incompatible with a primary neoplasm in the biopsy area, whose origin 
is not clear, despite performing a thorough clinical history, a complete physical 
examination, and basic complementary studies.14–16  However, this definition is not an 
international standard as reflected in diagnostic codes, and varies between institutions 
and countries.17–19 As a result of this challenging situation, complete 
immunohistochemistry tests or post-mortem examination reveals the primary tumor in 
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only one in four (25%) CUP cases. The primary tumor of the majority of CUPs (75%) 
cannot be identified.20  
Epidemiological studies involving CUP cases are scarce and difficult to compare with 
each other, mainly due to the aforementioned differences in inclusion criteria.  The 
available studies, mainly from northern European countries (Netherlands,13 Sweden21–23, 
Scotland17 and Norway24), Australia25 and USA,26 cover half a century of historical data 
(1960–2010), and highlight the distinctive trends of this disease.  They reveal an 
increasing incidence of CUP over the period from 1960 to 1980, to a level of 16 per 
100,000 inhabitants.  Interestingly, although there are differences depending on the start 
year for each of the populations analyzed, there has nevertheless been a clear reduction 
in the incidence, whereby the figure now stands at 8 per 100,000 inhabitants. The 
reasons for such a reduction are thought to include advances in diagnostic methods at 
the biological, radiological and pathological levels, although it might also be a 
consequence of insufficient diagnostic inquiry, a phenomenon documented in the US 
population.  
Histologically, well-differentiated or moderately differentiated adenocarcinomas account 
for 50-70% of CUP cases, while poorly differentiated carcinomas/adenocarcinomas make 
up 20-30% of them. The remaining cases are divided into squamous cell carcinomas (5-
8%) and poorly differentiated or undifferentiated malignant neoplasms (2-3%).27 CUP 
appears from the age 30 years, with a peak at around 70 years. In terms of survival, 
although current data are very discouraging, attaining overall survival (OS) of 2.75-11 
months after diagnosis, with a 1-year survival rate of 15-20%, represents an improvement 
since the early 2000s where in a population based study the estimated median survival 
was just 11 weeks.13 The current improvement is thought to be a consequence of earlier 
detection and advances in the management of advanced-stage neoplasias. 
Clinical management of patients with CUP entails taking different steps towards deciding 
the appropriate treatment.  First, non-carcinoma neoplasms (sarcomas, melanomas and 
lymphomas) should be ruled out if possible. In 15-20% of cases there is a strong 
suspicion, either from immunohistochemical or molecular tests, of the presence of a 
primary cancer for which a specific and efficient treatment exists.  In such circumstances, 
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patients should receive the corresponding site-specific treatment, since, with appropriate 
management, long-term disease control can be achieved in 30-60% of cases.16  
Preliminary retrospective studies have shown an improvement in survival in patients 
treated with site-specific therapies for the equivalent primary tumor originating the 
metastasis.28  The other 80-85% of CUP cases have a very poor response to treatment, 
and without any suspicion of its primary tumor, its treatment involves an empirical 
schedule consisting of either taxanes or platins or a combination of the two, in 
conjunction with gemcitabine.29  The median survival of this group is a disheartening 6-9 
months, response rates are around 20%, and the 1-year survival rate barely reaches 
25%.30  Nevertheless, within this non-specific subset of patients, two prognostic groups 
can be identified on the basis of their performance status and lactate dehydrogenase 
(LDH) serum levels.  Patients in the first group, characterized by a good performance 
status and normal levels of LDH, are treated with empirical two-drug chemotherapy, 
resulting in a median life expectancy of 1 year.  The favourable subset include women 
with adenocarcinoma involving axillary nodes, and papillary adenocarcinoma of 
peritoneal cavity, patients diagnosed with squamous cell carcinoma involving cervical 
nodes, poorly differentiated neuroendocrine carcinomas, and adenocarcinomas with a 
colon-profile (CK20+, CK7−, CDX2+). However, patients in the second group, who have 
elevated serum LDH levels and/or poor performance status, have a median OS of only 4 
months, and depending on their performance status, best supportive care or 
chemotherapy is applied.31 The most common histological types are adenocarcinomas of 
moderate to poorly differentiated (64%), the rest been undifferentiated tumors. It involves 
mainly the liver in 40–50% of the cases, followed by lymph nodes (35%), lungs (31%), 
bones (28%) and the brain (15%).32 Additional independent prognostic factors include the 
age, number of metastatic sites, and neuroendocrine differentiation. 
Diagnostic tools in CUPs 
Until now, immunohistochemistry (IHC) based on the detection of particular antigens in 
tumor cells of a tissue section using specific antibodies, has been the main strategy for 
identifying the primary tumor of a given metastasis in routine clinical practice.33  Of the 
most commonly used markers, cytokeratins 7 and 20, high- and low-molecular weight 
keratins (34ßE12 and CAM.52, respectively) and tissue-specific markers, such as thyroid 
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transcription factor-1 (TTF1), mammoglobin, intestine-specific transcription factor (CDX2) 
and hepatocyte specific antigen 1 (HepPar-1), are of particular note.34,35  However, no 
hegemonic panel of IHC markers has been established, and instead multiple panels are 
used to address this challenge.35-40  Unfortunately, there is not a single specific marker 
which by itself can provide a conclusive diagnosis. Low reproducibility is another intrinsic 
limitation of this technique, in part due to the need to interpret IHC preparations, which, 
by their nature, involve subjective observation.  The aforementioned reasons are those 
that lead to the poor 50-65% success rates of conventional histopathological methods in 
the diagnosis of metastases in known primary tumors, the rate dropping to a mere 25% of 
cases when considering only CUP cases.34,41  
Besides immunohistochemistry, image diagnosis is used to localize the origin and to 
reach a diagnosis of CUPs.  Computer tomography (CT) and conventional magnetic 
resonance imaging have been extensively used to locate alterations compatible with the 
clinical manifestation of CUP. However, the small size of the primary tumor or the 
regression of the primary tumor could occur in CUP cases, hindering their diagnosis.34 
The use of 18F-fluoro-2-deoxyglucose positron emission tomography/computed 
tomography (FDG-PET/CT) successfully facilitates this task.42-48  However, although this 
technique is very specific (71%) and sensitive (87%) at detecting CUP primary lesions,49 
it has a poor detection rate that rarely exceeds 40% in identifying the primary tumors of 
patients with CUP.50  
Complementary to histological and imaging analysis, the dissemination patterns of 
tumors are taken into account in clinical protocols to identify the primary origin of CUP.  
For instance, metastases located in the liver most frequently originate in the 
gastrointestinal tract, lung, breast, genitourinary tract or uvea; the primary tumors of lung 
metastases are usually located in the breast, gastrointestinal tract, kidney or prostate.  
Overall, it is not surprising that daily clinical practice for the treatment of CUP suffers from 
a high degree of diagnostic uncertainty, mainly due to the strong discrepancies between 
the cytological, histological and immunohistochemical diagnoses performed in a given 
CUP case.51  Moreover, the idiosyncrasy of the disease itself predisposes towards 
diagnostic confusion, since the tumors are very often poorly differentiated, or completely 
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undifferentiated,52 hindering their correct diagnosis.  This challenging situation translates 
directly into a low success rate of diagnostic work-up in CUP, with only 20-30% of the 
cases being successfully diagnosed.  
Unlike immunohistochemical panels, in which the expression of only a small number of 
genes is tested, and whose interpretation is subjective more than quantitative, gene 
expression profiling was introduced for cancers of unknown diagnosis in 2005 as a new 
approach to study in a quantitative manner the expression profiles of larger panels of 
genes characteristically and differentially expressed in different tumor types.53-59 This 
approach enabled the prediction of the tissue of origin in a CUP by comparing its 
expression profile with that of a set of primary/metastatic tumors of known origin.  
Applying this method to primary and metastatic tumors of known origin enabled the 
correct identification of 83-89% of cases. Moreover, 91% accuracy in the prediction of 
tissue of origin in poorly differentiated and undifferentiated carcinoma metastases is 
achieved, although the figure drops to 71% of cases when IHC is the chosen diagnostic 
technique.57 These results show what could happen in the case of applying the prediction 
of tissue of origin in CUPs, in which results compatible with clinicopathological features 
and response to treatment are obtained in 94% of cases.54,57  Besides gene expression 
prediction, another interesting approach is the use of microRNA assays to identify the 
tissue of origin of CUPs; this gives similar results to those based on gene expression.60,61 
Table 1 summarizes the features of the most relevant studies that use expression profiles 
in CUP diagnosis. It is also important to note that all molecular assays assigning a 
primary tissue of origin to CUP are constructed in order to look for similarities (but not 
differences) between CUP and metastatic solid tumours. However, the peculiar behavior 
of CUP hints for the existance of molecular differences between CUP and Known Primary 
metastases that have been overlooked so far in the developed diagnostic pipelines. In 
addition, for the described assays, there are limitations in the cohort patient size and the 
tumor types, the requested amount and state of preservation of the analyzed clinical 
sample, and the overall cost of the assessment, that warrant the development of 
additional molecular profiling tools for cancer of unknown primary. To address the unmet 
medical need in this area with the dismal survival of the CUP patients, the use of 
epigenetic biomarkers62,63 is worth to be explored.   
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Epigenetics in cancer diagnosis 
Epigenetic mechanisms are generally understood to be those that regulate gene 
expression. The epigenetic code is characterized as being inherited throughout cell 
division and even transgenerationally.64  Covalent addition of methyl groups to the 
carbon-5 of cytosines in DNA is the predominant epigenetic mechanism in mammal cells, 
although chromatin remodeling also has an important role in controlling genes and 
ncRNAs expression, DNA-protein interactions, mobility of transposable element 
suppression, cellular differentiation, embryogenesis, X-chromosome inactivation and 
genomic imprinting.65  The ability of epigenetic marks to persist during development and 
potentially be transmitted to offspring may be necessary to generate the wide range of 
phenotypes that arise from the same genotype.64  
The importance of epigenetics in normal cell maintenance is reflected by the observation 
that the introduction of the wrong type of epigenetic marks at an inappropriate time or 
place is associated with development of many diseases, such as cancer.66  In this 
context, the global genomic loss of DNA methylation leads to alterations in chromosomal 
integrity.  In addition, hypomethylation at a specific promoter activates oncogenes and 
induces loss of imprinting (LOI) at some loci. DNA methylation is also important in that it 
causes a loss of expression of the tumor suppressor genes involved in cell cycle, 
apoptosis, and proliferation, which may in turn contribute to cancer progression.7  
In spite of huge advances in cancer diagnosis, there are still many cancer cases that 
have unexpected progress or that are unclassified as known tumor subtypes. Indeed, 
tumors with the same histopathological and genetic characteristics show completely 
dissimilar behaviors. This phenomenon could be the consequence of different epigenetic 
backgrounds. A recent example is the effect of the methylation status of TBC1D16 gene, 
which leads to differential prognosis in cohorts of melanoma BRAF V600E-mutated 
tumors.67 DNA methylation profiling has revealed cancer-specific signatures of 
hypermethylated CpG islands, by which we can distinguish tumor types and predict 
antineoplasic treatment responsiveness and patient outcome.9,68 Related to therapìes, 
Pharmacoepigenetics started with the original observation of the association between 
hypermethylation of MGMT and response to alkylating agents in gliomas69,70, a test that it 
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is used nowadays in clinical care. Other epigenetic markers have emerged in a similar 
manner such as BRCA1 hypermethylation to predict response to PARP inhibitors,71,72  
DERL3 hypermethylation as predictor of sensitiveness to glycolysis inhibitors,73 as well 
TBC1D16 hypomethylation as biomarker of higher sensitivity to BRAF and MEK 
inhibitors.67 Furthermore, epigenetic markers are also proficient to foresee response to 
treatment, such as SLFN11 or SRBC hypermethylation that is associated with resistance 
to platinum drugs.74,75  
Regarding this utility for more accurately classifying the tumors into already existing 
categories, it has been reported that aberrant DNA hypermethylation events in cancer-
related genes, such as BRCA1, are common features in the breast cancer triple-negative 
subtype.76,77 Key epigenetic alterations involved in the initiation and progression of cancer 
have also been described in other neoplasias, such as acute myeloid leukemia and renal 
cell carcinoma, highlighting their utility in early detection and differential diagnosis.78–80  
The detection of hypermethylated genes in stool and blood samples is a sensitive and 
specific way of assessing the risk of colon cancer, and for its early detection.81–83  
Moreover, hypermethylation events at APC, MGMT, RASSF2 and WIF1 genes can be 
detected in the plasma of patients with colon cancer with high sensitivity and specificity 
(87%).84  Another example is that prostate cancer can be diagnosed through the 
detection of hypermethylation at the GSTP1 gene in tissue biopsies, urine, plasma or 
ejaculate samples,85,86 with a high sensitivity and specificity (82% and 95%, respectively), 
and also in precursor lesions for the development of this tumor.  The use of DNA 
methylation as a potential biomarker for diagnosing other neoplasias, such as 
esophageal squamous cell carcinoma,87 non-small cell lung cancer88 and rectal cancer 
has also been described,89 highlighting the value of studying methylation as a diagnostic 
tool in cancer. For colorectal cancer90-92 and neuroblastoma,93,94 the described existance 
of several CpG islands that undergo a shared DNA methylation gain (“CpG island 
methylator phenotype”) also represents a useful biomarker tool for these malignancies. 
Epigenetic approach to CUP diagnosis 
The huge advances in understanding how the epigenetic machinery works, acts and 
interacts, and the implications of these for the proper functioning of cells, and how 
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epigenetic deregulation may lead to the development of cancer, has encouraged the 
search for DNA methylation features that, being present in CUP, might maintain the 
signature of the presumed primary origin.  
The observation that DNA methylation fingerprints provide important clues concerning the 
tissue-type identity was first made in a study of more than 1,000 human samples using a 
high-throughput approach that interrogated 1,505 CpG sites and was able to discriminate 
24 different tumor types.9  Until then, most of the studies characterizing DNA methylation 
patterns had been restricted to examining particular genomic loci in a limited number of 
human samples. The study analyzed 42 CUPs and it was able to assign a given tumor 
type for these CUPs in 69% of cases using L1-regularized logistic regression with 
misclassification to create a prediction heatmap.9 A proposed foster primary in these 29 
cases was also achieved by conventional clustering analysis. The tumor type prediction 
of the CUPs based on the DNA methylation analyses was fully confirmed in 78% of cases 
for which detailed pathological analysis developed at a later stage in a blind fashion was 
able to provide a diagnosis (Table 1).9 Certainly, the DNA methylation patterns identified 
in that study across the largest spectrum of samples constituted a baseline for developing 
higher-resolution DNA methylation maps and providing important clues about the 
contribution of DNA methylation to tissue uniqueness. Based on these results and with 
the aim of developing a sufficiently robust diagnostic tool for use in clinical practice, a 
CUP classifier based on DNA methylation profiling (EPICUP) was generated that enabled 
the tissue of origin to be predicted in 87% of cases,10 (Table 1) representing a huge 
improvement on the 25% of cases identified using light microscopy and IHC testing.20 
This could not have been achieved without the dramatic improvements made in the field 
of new-generation technologies in DNA methylation analysis,95,96 which have generated 
large amounts of information highlighting the role of epigenetics in personalized 
oncology.97 In an initial discovery phase, 2,790 primary tumor and metastasis samples 
from 38 tumor types of known origin, including the most common human cancers, were 
analyzed using Infinium HumanMethylation450K BeadChip (Illumina), a high-resolution 
method that interrogates more than 485,577 CpG sites and covers 99% of RefSeq 
genes.95  A classifier algorithm was generated and evaluated with a secondary validation 
cohort that included 7,691 samples, resulting in a highly accurate predictive tool (99.6% 
specificity and 97.7% sensitivity), with a positive predictive value of 88.6%. These are 
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higher values than those obtained with other molecular platforms previously generated for 
the diagnosis of CUP.55,59  For clinical application, primary and metastatic tissues were 
classified with equivalent precision, as were both frozen and formalin-fixed paraffin-
embedded (FFPE) tissue samples. Analysis of these did not reveal any different results, 
as had been previously demonstrated.98  Further, the effectiveness of EPICUP as 
predictor of tumor origin was demonstrated using a cohort of 216 CUP cases collected 
from various countries.10  The median age of the cohort was 63 years, with most of its 
members presenting multiple metastasis sites at diagnosis (60%); 
adenocarcinomas/carcinomas accounted for 66% of cases and the median survival was 9 
months, these values being similar to those for a representative CUP population.27  
Lymph nodes were the main site of biopsy at the moment of diagnosis (29% of cases), 
and the tumor type most frequently predicted by EPICUP was non-small cell lung cancer 
(20.6% of cases), in accordance with data previously reported about the origin of CUP in 
necropsies (Figure 1).27 
EPICUP has proved to be reliable according to the best available knowledge of the 
clinical and pathological description of each CUP case.  In one case, the tissue of origin 
was determined at necropsy and was corroborated by immunohistochemistry. 
Interestingly, the tissue of origin was found to be the same as that previously predicted by 
the DNA methylation-based classifier (sarcoma) (Figure 2A).  In other cases, EPICUP 
guided IHC analysis with proper specific markers that confirmed the prediction.  An 
unusual case was that of a male with lesions in the axillary lymph nodes, who was 
diagnosed as CUP after clinical and histopathological evaluation, and was then treated 
with empirical chemotherapy.  At progression, the CUP was subjected to the classifier, 
which yielded a prediction of breast cancer that was subsequently corroborated by 
mammoglobin-positive staining. The condition was then treated appropriately (Figure 
2B).  Similar observations were made of other tumor types, such as the determination of 
CDX2-positive staining in a colon cancer case after being correctly predicted by EPICUP 
(Figure 2C). Another clear advantage of this epigenetic approach is that is based on 
DNA, a molecule that is stable over time, regardless of the method of tissue fixation, and 
so not one predisposed to change due to minimal external factors, unlike RNA expression 
levels. Moreover, tumor type predictions were reproducible using DNA methylation 
profiling with two methylation microarrays, 450K95 and 850K.96 Both of these are useful 
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for analytical purposes.  In summary, the use of methylation to predict the tissue of origin 
is a potent strategy that may be applied in CUP diagnosis in conjunction with clinical and 
histopathological tests.20 
Present and future challenges  
The use of molecular platforms in the clinical management of human cancer is now a 
reality.  Our better knowledge of cancer biology and behavior has allowed a more 
accurate classification of neoplasias, resulting in optimized cancer diagnosis, prognosis 
and tailored therapy.  A good example is the case of patients with CUP, for whom this 
DNA methylation-based classifier, as well other types of molecular platforms, is and will 
be a key component of diagnostic workflow and clinical management. It is expected to 
have a significant effect on the quality of life and longevity of these patients.  
Nevertheless, essential and crucial steps are still necessary in order to facilitate its use in 
daily clinical practice and to guarantee its inclusion in CUP management guidelines. 
Impact on survival 
A retrospective study performed in a cohort of CUP patients with suspected tissue of 
origin in the colon provided support to the hypothesis that the administration of site-
specific chemotherapy consistent with the molecularly predicted tissue of origin produces 
a benefit in terms of survival rates in patients with CUP.99  Such an observation has also 
been supported by our retrospective work,10 in which we observed that those patients 
whose treatment was specific to the methylation-based tissue of origin prediction showed 
longer OS than those CUP patients who did not receive the best treatment available 
(empirical treatment) for their epigenetically predicted origin (13.6 versus 6 months, 
respectively). Nevertheless, a prospective non-randomized study has been reported,100 in 
which RT-PCR molecular tumor profiling was performed on biopsy specimens from 
patients diagnosed with CUP. Site-specific treatment was administered on the basis of 
the tissue of origin predicted by the assay, while those patients for whom the assay was 
unable to predict a tissue of origin were treated with standard empirical chemotherapy. 
The results indicated that CUPs treated with site-specific therapeutic schedules improved 
their median survival to 12.5 months, which a 38% improvement is compared with the 
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value of 9 months noted in the empirically treated CUP patients.  Moreover, patients 
whose predicted origin was a responsive tumor type and whose molecular profile was 
confidently predicted (probability of tissue of origin ≥ 80%) achieved longer survival 
(median survival of 15.4 months; 49% 2-year survival rate) when treated with a site-
specific therapy compared with patients with less responsive tumor types and less certain 
predictions (median survival of 7.0 months). Indeed, with an increasing number of 
effective molecularly targeted therapies available, an assay prediction may lead to the 
identification of additional therapeutic options, such as targeted therapies. Although this 
prospective clinical trial has not fully answered the question of whether site-specific 
treatment in CUP patients is unequivocally favorable in terms of survival, this could be 
resolved by a fully randomized clinical trial in which patients are randomly divided into two 
arms, one being treated with site-specific schedules, the other arm receiving empirical 
CUP chemotherapy. However, although it might be technically feasible, this clinical trial 
approach has some difficulties. For example, a percentage of CUP patients have cancer 
types that could be not significantly affected by either standard therapy or empirical 
chemotherapy. Moreover, even among tumor types such as those of ovarian, breast, 
non-small cell lung and bladder cancers, which are considered to be more responsive to 
chemotherapy, their first-line empirical CUP therapy is similar to standard site-specific 
therapy. Nonetheless, and recently summarized in an editorial in the journal,101 there are 
enough data to support the concept that molecular profiling in CUP diagnosis leading to 
the administration of a  specific treatment according to its predicted origin improves 
survival rates of these patients.58,60,100,102  Future perspectives include the creation of a 
clinically useful diagnostic algorithm, which would incorporate pathological findings and 
molecular profiling tests along with crucial clinical judgment to maximise clinical benefit 
and limit costs. However, it is a must the development of high quality, prospective and 
randomized clinical trials to confirm that primary-tissue tailored therapy does indeed 
result in improvement of patient survival in CUP. 
Screening of drug-actionable alterations 
Only 25% of cases of CUP receive a single putative primary tumour diagnosis using light 
microscopy and immunohistochemical testing. An algorithm that integrates 
immunohistochemistry, tissue-of-origin profiling, and comprehensive genomic profiling in 
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some combination may maximize clinically meaningful benefit and minimize costs. A 
sizable percentage of patients with CUP will not currently benefit from assay-directed 
therapy, because effective therapy for these tumor types does not currently exist. The 
correct determination of the primary site of origin by EPICUP could guide the screening of 
drug-actionable mutations. The observation that patients with CUP who received a 
tumour type-oriented treatment did better than those receiving non-specific therapy might 
also be associated with an inherently different prognosis, regardless of the received 
treatment. 
In fact, molecular-based prediction of tissue of origin in orphan metastases could have 
significant implications for the management of CUPs, given that revealing the tissue of 
origin might be useful for determining whether the sample carries any drug-actionable 
alteration that would make patients candidates for achieving better survival rates.103  In 
this regard, next generation sequencing of CUP cases have identified that many of these 
lesions harbor targetable genomic alterations,104,105 such as those shown in Figure 3. 
Strikingly, a higher incidence of mutations in the C-MET gene (around 30%) has been 
found in the CUP population compared with the frequency in solid tumors (around 4%).106  
Other clinically relevant genetic alterations that have been detected in metastases of 
unknown primary that are targetable, include EGFR mutations, HER2 amplification and 
ALK translocation, among others,10,107 Importantly, the correct determination of the 
primary site of origin by EPICUP and other methods could guide targeted therapies, 
because if we search for actionable mutations without knowledge of the precise cellular 
context some surprises may arise.108  For example, a K-RAS mutation in a patient that 
EPICUP predicts to be a non-small cell lung cancer with hylar nodes plus brain 
metastasis may have different clinical implications compared with an EPICUP-diagnosed 
colorectal cancer patient sharing that K-Ras mutation. Another illustrative case would be 
the discovery of a BRAFV600 mutation: if the DNA methylation profile predicts melanoma 
or thyroid carcinoma, the targeted therapy would be more adequate than if the EPICUP 
system indicated that the primary site was a colorectal tumor. The same scenario maybe 
true for epigenetic markers of drug sensitivity: if MGMT promoter hypermethylation has 
proved to be the best predictor of good clinical response to alkylating agents in 
gliomas,69,70 it only shows a more modest capacity to predict sensitivity to the same 
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agents in colorectal tumors.109,110  Figure 3 illustrate how the determination of the primary 
site can be helpful for the right selection of the tailored-treatment.  
However, the field is young and the available quality data establishing that therapy 
targeting molecular aberrations of a CUP does indeed result in improvement of patient 
survival are very scarce. For example, in an EPICUP studied sample,10 the epigenetically 
predicted origin was a non-small cell lung cancer and it carried an EGFR-mutation 
(G719X). The patient had received a specific treatment with erlotinib and achieved long 
survival (Figure 4).10  In another study, the treatment of a CUP case harboring C-MET 
gene amplification led to a complete clinical response greater than 3 years,111 whereas a 
CUP patient with an ALK fusion responded dramatically to crizotinib therapy.112  
Furthermore, CUP cases can also be great candidate to participate in aberration-specific 
clinical studies, the so called “basket trials” to improve the survival of these patients. 
Importantly, it is now possible to apply technologies based on next-generation 
sequencing that allow the interrogation at the same time of different phenomena at the 
DNA level, such as methylation fingerprinting and drug-actionable alterations that wil 
provide a more complete picture of the molecular profile of any given CUP case. 
The establishment of an international CUP consortium with a virtual tissue bank storing 
clinically annotated CUP biological material in various centres would enhance our ability 
to perform correlative translational research projects within or outwith trials. There is 
retrospective evidence that the biologically genuine CUP is the visceral CUP subgroup. 
An inherent problem is that these patients harbor tumours not markedly impacted by 
either standard therapy or empiric chemotherapy. Ideally, a prospective trial would 
classify visceral CUP by EPICUP to a tissue of origin, followed by randomization to 
tissue-independent empiric chemotherapy versus tissue-guided optimal chemotherapy 
combined with targeted therapy. Intention-to-treat analysis of overall survival, quite dismal 
in this subgroup of visceral CUP patients, would be an endpoint not confounded by 
salvage therapies and mature enough in relatively short follow-up times. Alternatively, 
EPICUP could be used in retrospective or prospective cohort studies looking at outcome 
differences between typical metastatic solid tumours of known primary versus CUPs with 
EPICUP-identified matched primaries. Such a cohort study could provide hints at 
biological peculiarities of CUP. 
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Optimization of DNA methylation in single-cell and liquid biopsies 
We are currently in an era of technological transition leading to a reduction in the 
invasiveness and a greater personalization of diagnostic tests.  The times of using a 
sledgehammer to crack a nut are over, and more refined approaches are now gaining 
momentum.  As an example, obtaining the DNA methylome of the whole tumor, although 
providing very useful information, might not be the optimal approach since each tumor 
might have a different cell composition.113  Obtaining single cell profiles, which requires a 
minimal sample, is now feasible,114,115 and with sequencing costs falling, its use in 
diagnostic testing is becoming more attractive. Single-cell approaches have not been 
applied in CUP, although they might lead us to a better understanding and means of 
diagnosing CUP. An intermediate approach would be to analyze circulating tumor cells, 
since this might enable us to understand the absence of primary tumors originating CUP.  
The value of this approach in providing predictive biomarkers of patient outcome has 
been reported,116 although we currently lack an approach with which to characterize their 
genomic material with respect to distinctive alterations. In this regard, other types of 
epigenetic patterns, such as histone modifications, can be studied in this context. It is 
known that histone modification patterns undergo significant aberrations in human 
tumors.117,118  Importantly, we have now powerful techniques to study not only particular 
histone modifications starting with few cells,119-121 but also to measure tissue-type specific 
patterns of chromatin accesibility.122,123  Another interesting advance is the incipient use 
of liquid biopsies, in which circulating cell-free DNA is interrogated for biomarker 
alterations. This approach will obviate or minimize the need for intrusive diagnostic 
biopsies, a less-intrusive blood extraction method being available instead to provide 
enough material to perform the diagnostic procedures. We have been able to detect the 
presence of aberrant hypermethylation of tumor suppressor genes in serum DNA since 
the late 90s.124,125  However, it has been the introduction of more sensitive and quantified 
techniques to analyze DNA methylation, such as it has been as shown for diffuse large B 
cell lymphoma,126 and hepatocellular carcinoma,127 that can facilitate its translation to the 
clinical setting. In this regard, although this approach has not been directly reported in 
relation to defined CUP samples, very promising results have been recently obtained to 




Cancer of unknown primary is a heterogeneous disease defined by the presence of 
metastatic lesions with no identified primary tumor at presentation, resulting in an 
extremely poor outcome for patients, in part due to the lack of information with which to 
chose the most suitable treatment.  The huge advances in molecular platforms have 
improved our ability to recognize the tumor of origin in CUP, which is correctly identified 
by conventional diagnostic tools in only 30% of cases. This progress has had a 
demonstrable influence on extending survival.  In particular, the DNA methylation-based 
classifier EPICUP has correctly identified the tumor of origin in a higher proportion of 
patients than have older established approaches, and with more confidence than with 
other gene expression-based platforms.  Prediction of tissue of origin might serve as a 
clue to interrogate particular genetic alterations for which specific treatments exist (drug-
actionable targets). Prospective clinical trials are underway to assess the real impact of 
these platforms on survival. 
EPICUP has begun to be implemented, in conjunction with current diagnostic strategies.  
Their application in clinical care supposes an advance in classification of these tumors, 
homogenizing their management in the different health centers and increasing the current 
poor survival rates associated with this disease. The suitability of the analysis of 
methylation as diagnostic tool in the clinics had already been demonstrated, in part 
because the stability of DNA means that it does not easily react to changes caused by 
external factors, and because it is relatively straightforward to detect in samples that are 
easily obtained in the course of daily clinical practice, such as FFPE or liquid biopsies.  
Likewise, the great capacity for expansion of this epigenetic-based tool could give rise to 




 Knowing the tissue of origin leads to improved management and prognosis of 
CUP patients. 
 Advances in molecular platforms have enabled CUP diagnosis to be optimized. 
 DNA methylation is a valid biomarker for clinical diagnosis and has the capacity to 
discriminate different tissues. 
 Epigenetic prediction of tissue of origin improves CUP diagnosis, being more 
robust than other molecular-based platforms. 
 Prediction of tissue of origin might serve as a first clue to determine particular 
genetic alterations for which specific treatments exist (drug-actionable targets). 
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December 1st 2016.  The search produced 8,260 hits, which, after filtering out those that 
were not related to CUP, or were duplicated entries, or for which no abstract was 
available, the list was reduced to 837 scientific articles. 
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Figure 1. Biopsy sites and frequencies of tumor types predicted by EPICUP. 
Frequency of sites (left) where orphan metastases were biopsied from the EPICUP study.  
Representation of the frequency of tumor type predicted by EPICUP (right). Those sites 
or tumor types with frequencies <1% are not shown. Ca.: carcinoma; CNS: central 
nervous system neoplasia; HCC: hepatocellular carcinoma; HNSC: head and neck 
squamous carcinoma; NSCLC: non-small cell lung cancer; Uroth.: urothelial. 
Figure 2.  Examples of histopathological validation of CUP cases whose origin was 
predicted by EPICUP.  a) CUP case predicted by EPICUP as sarcoma: histopathological 
validation of the tumor sample after necropsy, using hematoxylin–eosin (H&E) staining 
and immunohistochemistry, which was shown to be positive by the specific sarcoma 
marker vimentin. The S100 marker, unrelated to sarcoma, was negative.  b) Predicted 
breast cancer CUP case by EPICUP, showing H&E staining, cytokeratin (CK) markers 
CK 7 (positive) and CK 20 (negative) and the specific breast marker mammoglobin that 
confirmed the breast cancer diagnosis. c) CUP case predicted by EPICUP as colon 
carcinoma, showing H&E staining, the cytokeratin markers CK 7 (negative) and CK 20 
(positive), and the specific colon marker intestine-specific transcription factor (CDX2) 
positive, validating the colon cancer diagnosis.  
Figure 3. Illustration of how the determination of the primary site in CUP cases can 
be helpful for the right selection of the tailored-treatment. 
Figure 4.  CUP patient who received a site-specific treatment that matched the 
EPICUP prediction and a guided search for “actionable” molecular targets.  CUP 
case that epigenetic profiling predicted to be derived from a non-small cell lung cancer 
(NSCLC) primary, a diagnosis validated by hematoxylin–eosin (H&E) staining and IHC 
studies with the cytokeratin (CK) markers CK 7 (positive) and CK 20 (negative) and the 
specific lung marker TTF-1 (thyroid transcription factor-1), in which a G719X EGFR 
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